1. Bristol-Myers Squibb Company (2017) Package Insert: GLUCOPHAGE® - (metformin hydrochloride) Tablets and GLUCOPHAGE® XR - (metformin hydrochloride) Extended-Release Tablets. Princeton, NJ; 1–35
2. Eli Lilly and Company (2018) Instructions for Use: TRULICITY® (Trū-li-si-tee) (dulaglutide) injection, for subcutaneous use – 0.75 mg/0.5 mL Single-Dose Pen once-weekly. Indianapolis, IN; 1–6
3. Eli Lilly and Company (2022) Highlights of and Full Prescribing Information: MOUNJARO™ (tirzepatide) injection, for subcutaneous use. Indianapolis, IN
4. Novo Nordisk A/S (2017) Highlights of and Full Prescribing Information: OZEMPIC® (semaglutide) injection, for subcutaneous use – 0.5 mg/1 mg. Plainsboro, NJ
5. American Diabetes Association (2019) Pharmacologic approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 44(Suppl 1):S111–S24